Full Length Research Paper
References
|
Berrettini W (2003). Evidence for shared susceptibility in bipolar disorder and schizophrenia. Am. J. Med. Genet.123C:59-64. |
|
|
Bly M (2005). Mutation in the vesicular monoamine gene, SLC18A1, associated with schizophrenia. Schizophr. Res. 78:337-338. |
|
|
Brunk I, Blex C, Rachakonda S, HoltjeM, Winter S, Pahner I, Walther DJ, Ahnert-Hilger G (2006). The first luminaldomain of vesicular monoamine transportersmediates G-protein-dependent regulationof transmitter uptake. J. Biol. Chem. 281:33373-33385. |
|
|
Charney DS, Deutch A (1996). Afunctional neuroanatomy of anxiety and fear: implications for the pathophysiology andtreatment of anxiety disorders. Crit. Rev. Neurobiol.10:419-446. |
|
|
Chen SF, Chen CH, Chen JY, WangYC, Lai IC, Liou YJ, Liao DL (2007). Support for association of the A277Csingle nucleotide polymorphism in humanvesicular monoamine transporter 1 gene withschizophrenia. Schizophr. Res.90:363-365. |
|
|
Cordeiro ML, Gundersen CB, Umbach JA (2002). Lithium ions modulate the expression of VMAT2 in ratbrain. Brain Res. 953:189-194. |
|
|
Cordeiro ML, Gundersen CB, Umbach JA (2004). Convergent effects of lithium and valproate on theexpression of proteins associated with large dense core vesicles in NGF-differentiated PC12 cells. Neuropsychopharmacology 29:39-44. |
|
|
Cordeiro ML, Umbach JA, Gundersen CB (2000). Lithium ions Up-regulate mRNAs encoding dense-corevesicle proteins in nerve growth factor-differentiated PC12 cells. J. Neurochem. 75:2622-2625. |
|
|
Eiden LE, Schafer MK, Weihe E, Schutz, B (2004). The vesicular aminetransporter family (SLC18): amine/protonantiporters required for vesicular accumulationand regulated exocytotic secretionof monoamines and acetylcholine. PflugersArch.447:636-640 |
|
|
Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E (1996). Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc. Natl. Acad. Sci. USA. 93:5166-5171. |
|
|
Haider S, Ballester B, Smedley D, Zhang J, Rice P,Kasprzyk A (2009). BioMart Central Portal-unified access to biological data. Nucl. Acids Res. 37:W23-W27. |
|
|
Handley SL (1995). 5-Hydroxytryptaminepathways in anxiety and its treatment. Pharmacol. Ther.66:103-148. |
|
|
Hansson SR, Hoffman BJ, MezeyE (1998). Ontogeny of vesicular monoaminetransporter mRNAs VMAT1 and VMAT2. I.The developing rat central nervous system.Brain Res. Dev. Brain Res. 110:135-158. |
|
|
Khalifa AM, Watson-Siriboe A, Shukry SG, Chiu WL, Nelson ME, Geng Y, Fischer-Stenger K, Porter JH, Stewart JK (2012). Thr136Ile polymorphism of human monoamine transporter-1 (SLC18A1gene) influences its transport activity in vitro. NeuroEndocrinol. Lett. 33(5):546-551. |
|
|
Lohoff FW (2010). Genetic Variants in the Vesicular Monoamine Transporter 1(VMAT1/SLC18A1) and Neuropsychiatric Disorders. In: Qing Yan (Ed). Membrane Transporters in Drug Discovery and Development- Methods and Protocols. New York: Humana press, pp. 165-180. |
|
|
Lohoff FW, Dahl JP, Ferraro TN,Arnold SE, Gallinat J, Sander T,Berrettini WH (2006). Variations in thevesicular monoamine transporter 1 gene(VMAT1/SLC18A1) are associated withbipolar I disorder. Neuropsychopharmacology. 31:2739-2747. |
|
|
Lohoff FW, Weller AE, Bloch PJ, Buono RJ, Doyle GA, Ferraro TN et al (2008a). Associationbetween polymorphisms in the vesicular monoamine transporter 1 gene (VMAT1/SLC18A1) on chromosome 8p and schizophrenia. Neuropsychobiology 57:55-60. |
|
|
Lohoff FW, Lautenschlager M, MohrJ, Ferraro TN, Sander T, GallinatJ (2008b). Association between variationin the vesicular monoamine transporter1 gene on chromosome 8p and anxiety related personality traits. Neurosci. Lett. 434:41-45. |
|
|
Lohoff FW, Hodge R, NarasimhanS, NallA, Ferraro TN, Mickey BJ, Heitzeg MM, Langenecker SA, Zubieta JK, Bogdan R, NikolovaY S, Drabant E, Hariri AR, Bevilacqua L, Goldman D, Doyle GA (2014). Functional genetic variants in the vesicular monoaminetransporter 1 (VMAT1) modulate emotion processing. Mol. Psychiatry. 19(1):129-139. |
|
|
Liu Y, Edwards RH (1997). The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu. Rev. Neurosci. 20:125-156. |
|
|
Peter D, Finn JP, Klisak, I, Liu Y, Kojis T, Heinzmann C, Roghani A., SparkesRS,Edwards RH (1993). Chromosomal localizationof the human vesicular amine transporter genes. Genomics.18: 720–723. |
|
|
Richards M, Iijima Y, Kondo H, ShizunoT, Hori H, Arima K, Saitoh O, Kunugi H (2006). Association studyof the vesicular monoamine transporter 1(VMAT1) gene with schizophrenia in aJapanese population. Behav. Brain Funct. 2:39-45. |
|
|
Senkowski D, Linden M, ZubragelD,Bar T,Gallinat J (2003). Evidencefor disturbed cortical signal processing andaltered serotonergic neurotransmission ingeneralized anxiety disorder. Biol. Psychiatry.53:304-314. |
|
|
Sievert MK, Ruoho AE (1997). Peptide mapping of the [125I]Iodoazidoketanserinand [125I]2-N-[(3_-iodo-4_-azidophenyl)propionyl]tetrabenazine binding sites for the synaptic vesiclemonoamine transporter. J. Biol. Chem.272: 26049–26055. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
